

Indiana	Current	%	%
Indices	Value	1 D	YTD
Sensex	72,832	0.3	0.8
Nifty	22,097	0.4	1.7
BSE Midcap	38,801	0.4	5.3
BSE Small cap	42,771	1.1	0.2
Sectors – Perfor	mance (BS	E)	
Telecom	2,469	2.3	9.0
Realty	6,906	1.8	11.6
Auto	48,250	1.5	14.3
IT	35,825	-2.0	-0.5
Tech	16,207	-1.5	1.7
Oil & Gas	27,165	0.2	18.0

Nifty Gainers/Losers	CMP	% Chg
HEROMOTOCO	4,684	3.6
MARUTI	12,338	3.6
UPL	470	3.2
LTIM	5,005	(3.0)
INFY	1,509	(2.9)
WIPRO	487	(2.7)

#### FII Trading activities in Cash

FII DII	Dat 22-Ma		N	et	MTD
DII	22-Ma	or_2/			
		11-24	-3,3	310	-5,137
	22-Ma	ar-24	3,7	65	6,974
igs. in Rs Cr.					
Global Indio	ces	Cur Va		% 1 D	% YTD
Dow Jones		39,3	314	(0.4)	4.2
NASDAQ		16,3	384	(0.3)	11.0
DAX		18,2	268	0.3	8.9
Nikkei 225		40,3	379	(0.2)	21.3
FTSE 100		7,9	18	(0.2)	2.5
Hang Seng		16,	542	0.4	(1.5)
Shanghai		3,0	27	0.0	2.2
Source: Bloom	berg; As	s on 7:3	0 am I	ST	
Forex Rate					
INR/USD		8	3.4	-0.3	-0.3
INR/EUR		9	0.2	0.6	1.9
INR/GBP		10	)5.0	1.1	0.7
INR/YEN (1	00)	5	5.2	-0.7	6.5

### Market Commentary

- Asian markets are trading mixed, as the U.S. market took a pause following a rally sparked by optimism over the Federal Reserve's interest rate stance in its latest meeting. Nikkei and Shanghai are trading lower by 0.20% and 0.19% respectively, while Hang Seng istrading higher by 0.25%.
- Indian Indices are expected to open on a flat note. GIFT Nifty was trading at 22,124 vs. Friday's Nifty Futures close of 22,165.
- US markets ended lower as weakness among technology stocks weighed on the markets, with semiconductor giant Intel (INTC) plunging to its lowest intraday level in over four months. The Dow Jones ended lower by 162 points or 0.41% to close at 39,313 and the NASDAQ ended lower by 44 points or 0.27% to close at 16,384.

### What's Inside

• Pick Of The Week: Navin Fluorine International Ltd.

### News in Focus

- Eicher Motors: The company has incorporated a wholly-owned subsidiary, Royal Enfield Europe BV in the Netherlands, to increase the non-motorcycle supply chain in Europe.
- UltraTech Cement: The company has commissioned 1 mtpa (million tons per annum) of brownfield cement capacity at Roorkee, Uttarakhand. With this, the capacity of said unit has been increased to 2.1 mtpa and the total grey cement manufacturing capacity in India to 138.39 mtpa.
- Rail Vikas Nigam: The company has signed an MoU with the Airports Authority of India (AAI) for the construction of a subway or underpass to connect the operational area to the Airport Authority of India residential colony in Kolkata. The estimated cost of the project is Rs 229 Cr.
- Hindustan Aeronautics: The company has signed a contract with the Guyana Defence Force (GDF) and the Guyana Government for the supply of two Hindustan-228 commuter aircraft along with the Manufacturer Recommended List of Spares (MRLS), ground handling equipment and ground support equipment, training, and hand-holding at a total value of 23.37 MUSD (~Rs 194 Cr).
- Reliance Industries: The company has received the board approval for the acquisition of 100% equity shares of MSKVY Nineteenth Solar SPV and MSKVY Twenty-second Solar SPV from MSEB Solar Agro Power. The acquisition move is in line with the terms of the tender awarded to Reliance for setting up an aggregate solar capacity of 128 MW spread across various locations in Maharashtra under the Mukhyamantri Saur KrushiVahiniYojana 2.0.



# **Pick of the Week**

23rd March, 2024

Navin Fluorine International Ltd





NFIL specializes in fluorine chemistry and manufactures a range of products including refrigeration gases, inorganic fluorides, and specialty organofluorines. Its portfolio encompasses synthetic cryolite, fluorocarbon gases, hydrofluoric acid,

fluorides, and specialty organofluorines. Its portfolio encompasses synthetic cryolite, fluorocarbon gases, hydrofluoric acid, and other fluorine chemicals. Additionally, the company provides contract research and manufacturing services. With manufacturing capacities for anhydrous and diluted hydrofluoric acid in India, NFIL serves various industries such as stainless steel, glass, oil and gas, abrasives, electronics, and life and crop sciences.

#### **Investment Rationale**

- A. Continued Strategic Investments in CDMO: NFIL intends to invest Rs 288 Cr in capital expenditures to establish a cGMP4 facility with a capacity of 200 KL in Dewas, split into two phases, to be funded by internal accruals. The first phase, with a capacity of 100 KL and an expenditure of Rs 160 Cr, is expected to be operational by the end of CY25. The commencement of phase 2 of the capital expenditure will depend on the progress of the MSA and business projections.
- B. CDMO outlook remains strong: The company has broadened its Master Service Agreement (MSA) with European API customers to encompass two new molecules, bringing the total to three. These molecules serve as intermediates to a patented commercial product, showing promising prospects. Starting from FY26, the MSA is anticipated to make a substantial contribution to CDMO revenue. The proposed cGMP4 phase 1 capacity is essential to support the MSA and unlock the business vertical's \$100 million topline aspiration.
- C. Q4 to be better than Q3 due to Deferred Orders: Global Agro-Chem majors have postponed orders, aiming to reduce high-cost channel inventory, which has impacted the company's specialty chemical business but has led to an improvement in working capital. The ramp-up of the HFO Plant at Dahej is progressing slower than anticipated, with revenue expected in FY25E, and the company is collaborating with Honeywell to resolve the issue. Q4 is projected to outperform Q3, with sequential margin improvement anticipated.
- D. Optimum Utilization of Ref Gas Capacity: The company indicated that the R22 and R32 capacity is currently operating at its maximum capacity. In FY25, it is expected that Honeywell's capacity could yield peak revenues of INR 4.6 Bn
- E. Outlook & Valuation: NFIL remains dedicated to long-term investments within a prudent financial framework. With CDMO expected to drive growth, NFIL's history of effective execution and business attraction is a key advantage. Moreover, NFIL's emphasis on specialty chemicals, along with strategic capital expenditure in its traditional sector, is poised to fuel future revenue expansion. As such, we assign a target price of Rs. 3,430 per share, based on a 32x Sep'26E EPS valuation, indicating an 11% upside from the CMP.
- F. Recommendation: We recommend a BUY on the stock for a target price of Rs 3,430/share, implying an upside of 11% from CMP.

#### **Financial Summary (Consolidated)**

Y/E March	Net Sales (Rs Cr)	EBITDA (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	PER (x)	ROE (%)	ROCE (%)	EV/EBIDTA (x)
2023	2,077	550	375	76	41	17%	36%	29.4
2024E	2,086	419	270	54	57	11%	18%	39.4
2025E	3,002	756	441	89	35	16%	29%	22.3
2026E	3,702	1,028	622	125	25	18%	37%	16.3

Source: Axis Securities; CMP as on 22<sup>nd</sup> March, 2024

CMP (Rs)	Target (Rs)	Potential Upside (%)
3,096	3,430	11%

### MARKET DATA

No. of Shares	4.96 Cr
Market Cap	15,335 Cr
52-week High / Low	4,922/2,900
BSE Code	532504
NSE Code	NAVINFLUOR

# Why NFIL Ltd

 Capex plans to support future growth trajectory

- ✓ Sharp focus on R&D
- Well-nurtured long-term relationship with customers



Axis Intellect: Intraweek Stocks for the week 26 Mar 2024 to 01 Apr 2024`

Name of Stock	Sector	Мсар
TATA CONSUMER PRODUCTS	Staples	Large Cap
Shyam Metalics and Energy Limited	Metals & min	Small Cap
Godrej Consumer Products Ltd.	Staples	Large Cap
Siemens Ltd.,	Industrials	Large Cap
Five-Star Business Finance Ltd.	NBFC	Small Cap
Aurobindo Pharma Ltd.	Healthcare	Mid Cap
Hindustan Aeronautics Limited	Industrials	Large Cap
Cyient Limited	IT	Small Cap
Eicher Motors Ltd.	Auto & Anc	Large Cap
Bharat Petroleum Corpn. Ltd.,	Oil & gas	Large Cap



# **Investment Picks**

Company	Recommendation	CMP	Target Price	% Upside
Aarti Drugs Ltd	BUY	456	570	25.1
Aarti Industries Ltd	BUY	655	735	12.2
ACC Ltd	BUY	2,441	2,750	12.6
Affle India Ltd	BUY	1,089	1,350	24.0
APL Apollo Tubes Ltd	BUY	1,516	1,850	22.0
Aptus Value Housing Finance India Ltd	BUY	317	425	34.2
Archean Chemical Industries Ltd	BUY	639	885	38.6
AU Small Finance Bank Ltd	BUY	564	680	20.5
Aurobindo Pharma Ltd	BUY	1,020	1,160	13.7
Bajaj Finance Ltd	BUY	6,763	8,810	30.3
Bandhan Bank Ltd	BUY	182	240	32.0
Bank of Baroda Ltd	BUY	260	300	15.5
Bharti Airtel Ltd	BUY	1,236	1,400	13.3
Birla Corporation Ltd	BUY	1,448	1,835	26.7
Britannia Industries Ltd	BUY	4,867	5,800	19.2
Can Fin Homes Ltd	BUY	747	885	18.5
CCL Products (India) Ltd	BUY	604	720	19.2
Cholamandalam Investment & Finance Company Ltd	BUY	1,089	1,375	26.3
CIE Automotive India Ltd	BUY	445	565	20.0
City Union Bank Ltd	BUY	136	160	18.1
Coal India Ltd	BUY	431	510	18.2
Coforge Ltd	BUY	5,544	6,905	24.5
CreditAccess Grameen Ltd	BUY	1,383	1,970	42.5
Cyient Ltd	BUY	1,962	3,000	52.9
Dabur India Ltd	BUY	522	635	21.6
Dalmia Bharat Ltd	BUY	1,959	2,470	26.1
Equitas Small Finance Bank Ltd	BUY	93	122	31.5
Ethos Ltd	BUY	2,646	3,100	17.2
Federal Bank Ltd	BUY	150	180	20.3
H. G. Infra Engineering Ltd	BUY	898	1,080	20.2
Happiest Minds Technologies Ltd	BUY	777	1,100	41.5
HDFC Bank Ltd	BUY	1,443	1,975	36.9
HealthCare Global Enterprises Ltd	BUY	340	410	20.7
Hero MotoCorp Ltd	BUY	4,685	5,550	18.5
Hindalco Industries Ltd	BUY	547	660	20.6
Hindustan Unilever Ltd	BUY	2,256	2,850	26.3
CICI Bank Ltd	BUY	1,090	1,250	14.7
DFC First Bank Ltd	BUY	78	100	28.1
ndiaMART InterMESH Ltd	BUY	2,679	3,000	12.0
TC Ltd	BUY	428	500	16.7
J.Kumar Infraprojects Ltd	BUY	622	800	28.6
JK Lakshmi Cement Ltd	BUY	856	1,000	16.8
ITL Industries Ltd	BUY BUY	201 424	300 565	<u>49.2</u> 33.2
Jyothy Labs Ltd KNR Constructions	BUY	255	310	21.4
Kotak Mahindra Bank Ltd	BUY	1,775	2,140	20.6
KPIT Technologies Ltd	BUY	1,387	1,750	26.2
Krishna Institute of Medical Sciences Ltd	BUY	2,022	2,300	13.7
_upin Ltd	BUY	1,608	1,785	11.0
Vanappuram Finance Ltd	BUY	173	230	33.1
MAS Financial Services Ltd	BUY	289	398	37.7
Minda Corporation Ltd	BUY	405	450	11.1



# **Investment Picks**

Company	Recommendation	CMP	Target	%
			Price	Upside
Mold-Tek Packaging Ltd	BUY	801	1,030	28.6
Nestle India Ltd	BUY	2,575	2,880	11.8
Nippon Life India Asset Management Ltd	BUY	449	585	30.3
P I Industries Ltd	BUY	3,798	4,200	10.6
Persistent Systems Ltd	BUY	7,967	9,570	20.1
Pitti Engineering Ltd	BUY	744	915	23.0
PNC Infratech Ltd	BUY	430	510	18.6
Praj Industries Ltd	BUY	532	635	19.4
PSP Projects Ltd	BUY	657	815	24.0
Relaxo Footwears Ltd	BUY	830	950	14.5
Sansera Engineering Ltd	BUY	999	1,220	22.1
Shree Cement Ltd	BUY	25,363	31,470	24.1
SIS Ltd	BUY	440	540	22.6
State Bank of India	BUY	746	860	15.2
Steel Strips Wheels Ltd	BUY	232	325	40.3
TVS Motor Company Ltd	BUY	2,051	2,350	14.6
Ujjivan Small Finance Bank Ltd	BUY	46	64	38.8
UltraTech Cement Ltd	BUY	9,687	11,110	14.7
UNO Minda Industries Ltd	BUY	649	750	15.6
V Mart Retail Ltd	BUY	2,010	2,450	21.9
Varun Beverages Ltd	BUY	1,403	1,550	10.5
Welspun Living Ltd	BUY	142	210	48.3
Westlife Foodworld Ltd	BUY	762	930	22.0



Index	СМР	% Chng	S2	S1	Р	R1	R2
Nifty	22,096.75	0.39%	21755	21925	22055	22225	22350
Sensex	72,831.94	0.26%	71765	72295	72705	73240	73650
Bank Nifty	46,863.75	0.38%	46395	46630	46800	47035	47210



Nifty started the week on a flat note and remained extremely volatile on either side throughout the week. Nifty closed at 22097 on 22<sup>nd</sup> March with a gain of 73 points on a weekly basis.

On the weekly chart, the index has formed a small bullish candle with shadows on either side, indicating indecisiveness among participants regarding the direction. The 20 SMA is placed at 22167, which may acts as crucial resistance. The chart pattern suggests that if Nifty crosses and sustains above the 22200 level, it would witness buying, leading the index towards 22300-22500 levels. However, if the index breaks below the 21900 level, it would witness selling, taking the index towards 21800-21600. On the daily chart, Nifty sustaining above its 50, 100, and 200-day SMAs indicates a positive bias in the medium term. Nifty continues to remain in an uptrend in the medium term. Hence, 'Buying on Dips' continues to be our preferred strategy. For the week, we expect Nifty to trade in the range of 22500-21600 with mixed bias.

The weekly strength indicator RSI has turned flat, indicating a lack of strength.

The trend-deciding level for the day is 22055. If NIFTY trades above this level, we may witness a further rally up to 22225-22350-22520 levels. However, if NIFTY trades below 22055 levels, we may see some profit booking initiating in the market, which may correct NIFTY up to 21925-21755-21630 levels.



# Trading Insights

# Insight from trading volumes

Script	СМР	Total Volume (x1000)	Monthly Avg Volume(x1000)	% Change
INFY	1,509	20,696	6,935	198.4%
HCLTECH	1,558	7,704	2,891	166.5%
WIPRO	487	15,165	6,320	139.9%
MARUTI	12,338	1,089	521	109.1%
UPL	470	7,300	3,608	102.3%
SUNPHARMA	1,609	5,169	2,557	102.1%
HINDUNILVR	2,257	3,774	2,177	73.4%

# Insight from delivery

Script	CMP	Total Delivery Volume(x1000)	Monthly Avg Delivery Volume(x1000)	%Change
BRITANNIA	4,865	300	158	90.0%
HDFCLIFE	624	4,197	2,310	81.7%
HINDUNILVR	2,257	2,662	1,540	72.9%
INFY	1,509	7,250	4,203	72.5%
BAJFINANCE	6,761	1,175	708	66.0%
NTPC	325	13,449	9,123	47.4%
BAJAJ-AUTO	8,945	361	260	39.1%

\*CMP-Closing Market Price



# Daily Support/ Resistance of Nifty Companies

2 11	of hing companies					
Company	CMP	<b>Pivot Point</b>	R1	R2	S1	S2
NIFTY 50	22,097	22,054	22,224	22,351	21,926	21,756
ADANIPORTS	1,282	1,275	1,295	1,309	1,261	1,241
ASIANPAINT	2,842	2,835	2,862	2,882	2,815	2,788
AXISBANK	1,033	1,037	1,044	1,054	1,026	1,020
BAJAJ-AUTO	8,945	8,892	9,104	9,262	8,733	8,521
BAJAJFINSV	1,588	1,594	1,604	1,620	1,577	1,567
BAJFINANCE	6,761	6,750	6,814	6,867	6,697	6,633
BHARTIARTL	1,236	1,234	1,247	1,258	1,223	1,210
BPCL	593	594	603	614	583	574
BRITANNIA	4,865	4,847	4,911	4,958	4,800	4,736
CIPLA	1,481	1,473	1,498	1,515	1,456	1,431
COALINDIA	432	432	436	440	428	424
DIVISLAB	3,431	3,441	3,467	3,502	3,406	3,380
DRREDDY	6,203	6,183	6,260	6,317	6,126	6,048
EICHERMOT	3,988	3,955	4,047	4,106	3,896	3,804
GAIL	174	174	176	178	173	171
GRASIM	2,224	2,217	2,240	2,257	2,201	2,178
HCLTECH	1,558	1,546	1,584	1,610	1,520	1,482
HDFCBANK	1,443	1,444	1,450	1,457	1,437	1,430
			7			609
HDFCLIFE	624	623	630	636	617	
HEROMOTOCO	4,684	4,646	4,774	4,865	4,556	4,427
HINDALCO	548	545	553	559	540	532
HINDUNILVR	2,257	2,251	2,271	2,286	2,236	2,216
CICIBANK	1,090	1,087	1,097	1,103	1,081	1,071
NDUSINDBK	1,512	1,502	1,531	1,549	1,483	1,454
NFY	1,509	1,512	1,526	1,543	1,495	1,480
OC	165	165	167	169	163	162
ТС	429	427	432	435	423	418
JSWSTEEL	825	822	836	848	810	795
KOTAKBANK	1,776	1,773	1,786	1,795	1,764	1,751
T	3,618	3,596	3,669	3,721	3,544	3,470
_TIM	5,005	5,009	5,074	5,142	4,941	4,876
M&M MARUTI	1,879 12,338	1,877 12,218	1,907 12,547	1,935 12,756	1,849 12,009	1,819 11,681
NESTLEIND	2,573	2,567	2,598	2,622	2,543	2,512
NTPC	325	324	328	330	322	318
ONGC	263	262	266	269	259	255
POWERGRID	276	275	279	282	272	268
RELIANCE	2,910	2,908	2,922	2,934	2,897	2,883
SBILIFE	1,501	1,490	1,522	1,543	1,469	1,437
SBIN	747	746	750	753	742	738
SHREECEM	25,366	25,364	25,496	25,626	25,234	25,102
SUNPHARMA	1,609	1,598	1,632	1,655	1,575	1,542
TATAMOTORS	980	972	994	1,008	958	936
TATASTEEL	152	151	154	155	149	147
TCS	3,911	3,901	3,948	3,985	3,864	3,818
ГЕСНМ	1,263	1,260	1,283	1,303	1,239	1,216
TITAN	3,707	3,685	3,749	3,791	3,643	3,579
ULTRACEMCO	9,682	9,671	9,763	9,844	9,590	9,497
UPL	470	466	478	486	459	447
WIPRO	487	486	492	497	481	474

Source: Axis Direct.



#### Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

- Axis Securities Ltd. (ASL) is a SEBI Registered Research Analyst having registration no. INH000000297. ASL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. ASL is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector bank and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.
- ASL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities and with the Association of Mutual Funds of India (AMFI) for distribution of financial products and also registered with IRDA as a corporate agent for insurance business activity.
- 3. ASL has no material adverse disciplinary history as on the date of publication of this report.
- 4. I/We, authors (Research team) and the name/s subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We (Research Analyst) also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or ASL or its Associate does not have any financial interest in the subject company. Also I/we or my/our relative or ASL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of ASL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or ASL or its associate does not have any material conflict of interest. I/we have not served as director / officer, employee, etc. in the subject company in the last 12-month period.
- 5. ASL or its Associates has not received any compensation from the subject company in the past twelve months. I/We or ASL or its Associate has not been engaged in market making activity for the subject company.
- 6. In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, ASL or any of its associates may have:
  - i. Received compensation for investment banking, merchant banking or stock broking services or for any other services from the subject company of this research report and / or;
  - ii. Managed or co-managed public offering of the securities from the subject company of this research report and / or;
  - iii. Received compensation for products or services other than investment banking, merchant banking or stock broking services from the subject company of this research report;

ASL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report.

#### Term& Conditions:

This report has been prepared by ASL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ASL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ASL will not treat recipients as customers by virtue of their receiving this report.



#### Disclaimer:

Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. ASL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advise necessarily a guide to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ASL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or investment banker, lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting this document.

ASL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that ASL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ASL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither this report nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alternations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.

#### Copyright in this document vests with Axis Securities Limited.

Axis Securities Limited, SEBI Single Reg. No.- NSE, BSE & MSEI – INZ000161633, ARN No. 64610, CDSL-IN-DP-CDSL-693-2013, SEBI-Research Analyst Reg. No. INH 000000297, SEBI Portfolio Manager Reg. No.- INP000000654, Main/Dealing off.- Axis Securities Ltd, Unit No.1001, 10th Floor, Level-6, Q2 Building, Aurum, Q Parc, Plot No. 4/1, TTC, Thane – Belapur Road, Ghansoli, Navi Mumbai. – 400 710., Regd. off.- Axis House,8th Floor, Wadia International Centre, PandurangBudhkar Marg, Worli, Mumbai – 400 025. Compliance Officer: Jatin Sanghani, Email: compliance.officer@axisdirect.in, Tel No: 022-49212706